Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Caught Off Guard As Mead Johnson Nutrition CO (MJN) Cuts Forecast

Page 1 of 2

Mead Johnson Nutrition CO (NYSE:MJN)‘s shares have slumped by over 2.0% today as the $17.14 billion infant formula maker cut its forecast for its 2015 sales and profits, citing a slowdown in the Chinese economy (the Chinese government would disagree with Mead Johnson’s assertion, as it has claimed 7% growth for the Chinese economy in the second quarter, as it had targeted). The world’s second-largest economy was responsible for 31% of the company’s sales last year compared to 24% from the U.S. While the sales growth forecast for the current fiscal year was cut to 2% from the 7% guidance provided in April, the EPS range was lowered to between $3.63 and $3.78 from the earlier indications of $3.90 to $4.00. Mead Johnson Nutrition CO (NYSE:MJN)’s stock reached a new 52-week low today on the disappointing news, but has since rebounded slightly.

Mead Johnson Nutrition CO (NYSE:MJN)

While a number of hedge funds pulled out of Mead Johnson Nutrition CO (NYSE:MJN) during the first quarter, the aggregate holdings of the funds increased rather substantially during a flat quarter for the stock. A total of 38 funds had about $1.12 billion in shares of the company at the end of the first trimester, as opposed to 42 firms with $883.69 million at the end of the previous quarter.

First a quick word on why we track hedge fund activity. In 2014, equity hedge funds returned just 1.4%. In 2013, that figure was 11.3%, and in 2012, they returned just 4.8%. These are embarrassingly low figures compared to the S&P 500 ETF (SPY)’s 13.5% gain in 2014, 32.3% gain in 2013, and 16% gain in 2012. Does this mean that hedge fund managers are dumber than a bucket of rocks when it comes to picking stocks? The answer is definitely no. Our small-cap hedge fund strategy, which identifies the best small-cap stock picks of the best hedge fund managers returned 28.2% in 2014, 53.2% in 2013, and 33.3% in 2012, outperforming the market each year (it’s outperforming it so far in 2015 too). What’s the reason for this discrepancy you may ask? The reason is simple: size. Hedge funds have gotten so large, they have to allocate the majority of their money into large-cap liquid stocks that are more efficiently priced. They are like mutual funds now. Consider Ray Dalio’s Bridgewater Associates, the largest in the industry with about $165 billion in AUM. It can’t allocate too much money into a small-cap stock as merely obtaining 2% exposure would really move the price. In fact, Dalio can’t even obtain 2% exposure to many small-cap stocks, even if he essentially owned the entire company, as they’re simply too small (or rather, his fund is too big). This is where we come in. Our research has shown that it is actually hedge funds’ small-cap picks that are their best performing ones and we have consistently identified the best picks of the best managers, returning over 139% since the launch of our small-cap strategy compared to less than 59% for the S&P 500 (see the details).

As far as insider trading surrounding Mead Johnson Nutrition CO (NYSE:MJN) is concerned, James Cornelius, who is one of the Directors of the company, purchased 10,000 shares this year, while Stephen Golsby, another Director disposed of 20,000 shares during the same period. It should be noted that insider purchases are a much stronger signal than insider selling.

Let’s dig deeper into the key hedgieaction encompassing Mead Johnson Nutrition CO (NYSE:MJN).

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!